Bone Therapeutics showcases allogeneic cell therapy data
Data demonstrated a 90% successful lumbar vertebrae fusion rate at 24 months
Read More
Tag: Bone Therapeutics
- Strong clinical data for Breye lead asset danegaptide
- EHP Awards triumph
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
